# Progentec Diagnostics, Inc.

> Progentec Diagnostics is an Oklahoma City company building blood-based biomarker tests and digital health tools for autoimmune diseases, starting with lupus. Its lead product, the aiSLE DX Flare Risk Index, uses an 11-biomarker algorithm to predict a lupus flare up to 12 weeks before it happens, giving rheumatologists a chance to intervene early. Spun out of research tied to the Oklahoma Medical Research Foundation, the company pairs lab science with patient-facing tools like the LupusCorner community to move autoimmune care from reactive to proactive.

- **Founded:** 2014
- **Headquarters:** Oklahoma City, United States
- **Founders:** Mohan Purushothaman (Co-Founder, Chairman, President & CEO), Melissa Munroe (Chief Scientific Officer & Principal Investigator)
- **Team size:** About 16 employees
- **Products:** aiSLE DX Flare Risk Index, aiSLE DX Disease Activity Index, aiSLE DX Lupus Classification / Diagnosis Test, LupusCorner
- **Notable:** Developed an algorithm that predicts lupus flares up to 12 weeks in advance using 11 blood biomarkers., Raised a $5M Series A backed by Mayo Clinic, Stanford and OMRF., Signed a distribution partnership making its tests available to all Mayo Clinic Laboratories clients in 2024.

## Products & services

- **aiSLE DX Flare Risk Index** — A blood-based laboratory test that uses 11 biomarkers and a weighted algorithm to estimate a patient's risk of a systemic lupus erythematosus flare in the next 12 weeks. Powered by LiquidFlareRisk technology.
- **aiSLE DX Disease Activity Index** — A blood-based test measuring current lupus disease activity, powered by LiquidDiseaseActivity technology, to guide ongoing management decisions.
- **aiSLE DX Lupus Classification / Diagnosis Test** — A biomarker test to aid in the classification and diagnosis of lupus.
- **LupusCorner** — An online community and mobile app offering information on lupus diagnosis, symptoms and daily living, plus access to chat with a nurse practitioner. Acquired by Progentec and used to power patient-reported outcomes and real-world evidence research.

## Achievements

- Developed an algorithm that predicts lupus flares up to 12 weeks in advance using 11 blood biomarkers.
- Raised a $5M Series A backed by Mayo Clinic, Stanford and OMRF.
- Signed a distribution partnership making its tests available to all Mayo Clinic Laboratories clients in 2024.
- Acquired the LupusCorner patient community and app to power real-world evidence research.
- Patients with a positive flare index score are nearly 5x more likely to experience a flare.

## Latest updates

- **2024-06** — Received a grant round of approximately $895K to support ongoing research and development.
- **2024-05** — Mayo Clinic Laboratories and Progentec launched advanced lupus biomarker testing services, making aiSLE DX tests available to all Mayo Clinic Laboratories clients.
- **2024-04** — aiSLE DX Lupus Flare Risk Index became orderable through Mayo Clinic Laboratories' test catalog effective April 25, 2024.

## Links

- Website: https://progentec.com
- LinkedIn: http://www.linkedin.com/company/progentec-diagnostics-inc-
- Twitter/X: http://twitter.com/ProgentecDX
- Facebook: http://facebook.com/mylupuscorner

---

Profile page: https://yespress.io/progentec-diagnostics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-06-13